印度或于下周批准使用阿斯利康新冠疫苗

India likely to approve AstraZeneca vaccine by next week

印度或于下周批准使用阿斯利康新冠疫苗

u=2806936177,3181491289&fm=11&gp=0.jpg

NEW DELHI: India is likely to approve Oxford/AstraZeneca’s coronavirus vaccine for emergency use by next week after its local manufacturer submitted additional data sought by authorities, two sources with knowledge of the matter told Reuters on Tuesday.

新德里：两位知情人士周二对路透社表示，在印度生产商提交了有关部门要求的额外数据后，印度可能在下周之前批准牛津-阿斯利康新冠疫苗用于紧急使用。

This could be the first country to give the regulatory green light for the British drugmaker’s vaccine as the British medicine regulator continues to examine data from the trials.

在英国药品监管机构继续审查试验数据之际，英国或成为第一个给英国制药商研发的疫苗开监管绿灯的国家。

India, the world’s biggest vaccine-making country, wants to start inoculating its citizens next month and is also considering emergency use authorisation applications for vaccines made by Pfizer Inc and local company Bharat Biotech.

印度是世界上最大的疫苗生产国，希望从下个月开始为国民接种疫苗，同时也在考虑为辉瑞公司和印度巴拉特生物技术公司生产的疫苗授予紧急使用许可。

Getting vaccines to the world’s second-most populous country with one of the highest infection rates will also be a big step in the battle against the pandemic.

向世界上人口第二多、感染率最高的国家之一提供疫苗，是抗击疫情的一大步。

The AstraZeneca-Oxford shot is considered vital for lower-income countries and those in hot climates because it is cheaper, easier to transport and can be stored for long periods at normal fridge temperatures.

阿斯利康-牛津疫苗对低收入国家和气候炎热的国家至关重要，这种疫苗更便宜，更容易运输，可以在正常的冰箱温度下长时间储存。

India's Central Drugs Standard Control Organization (CDSCO) first reviewed the three applications on Dec. 9 here and sought more information from all the companies, including from Serum Institute of India (SII), which is making the AstraZeneca shots.

印度中央药物标准控制组织(CDSCO)于12月9日首次审查了这三家公司的申请，并要求公司提供更多信息，包括生产阿斯利康疫苗的印度血清研究所(SII)。

India has not yet signed a vaccine supply deal with any company, but SII has already stockpiled more than 50 million doses of the AstraZeneca shot and plans to make a total of 400 million doses by July.

印度尚未与任何公司签署疫苗供应协议，但印度血清研究所已经储备了超过5000万剂阿斯利康疫苗，并计划到7月生产总计4亿剂疫苗。

印度时报读者的评论：译者：Jessica.Wu

Hindustani

Hope the vaccines will be available for common man soon.

希望普通人能尽快接种这些疫苗。

Dgdilip

The report rate says infection rate in india is highest. Thats a lie. The infection rate in indis much lower than US and UK.

报告称印度的感染率最高，这是一个谎言。印度的感染率远低于美国和英国。

Priyesh Sekar

May be give vaccine for free for underprivileged.. But not for those who are able to spend above 2000rs in liquor shops monthly..

可以给贫困人口免费接种疫苗，但不要给那些每月能在酒店消费2000卢比以上的人免费接种。

Frendu Pandey

We can't develope our own since nation is more interested in Mandir masjid gaay gobar...our cheap labor will be utilised by foreign company to manufacture their products....

我们研制不出本土疫苗，我们印度对疫苗不感兴趣，对寺庙更感兴趣…

我们的廉价劳动力被外国公司雇去生产产品....

Sudip Deb

When UK where the vaccine originated is yet to approve it why so hurry.

原产地英国还没有批准，印度为什么要这么着急。

Gugu Great

Good News finally

终于有好消息了

Maderna is way better than than pfiser and astazeneca .

印度本土新冠疫苗Maderna 比辉瑞和阿斯利康的新冠疫苗好得多

I hope india wont rush intoit. No other country have approved oxford yet.

目前还没有一个国家批准使用牛津疫苗，我希望印度不要仓促行事。

Prasenjit Das

India should also pursue other leading vaccine candidates to be on the safer side.

为了安全起见，印度还应考虑其他主要候选疫苗。

Sham Nv

Why it's so slow approval process? Babus waiting for Bribe money as usual?

审批过程为何如此缓慢?

先生们像往常一样等着收贿赂?

Middle Class

It is interesting a UK based company has not been able to get it approved in the UK till now but will be approved in India.

有趣的是，一家总部位于英国的公司到目前为止还没有在英国获得批准，却要在印度获得批准了

prabhunamadevan prabhunamadevan

Great news..

好消息

Swatantrate Bhagawati

Go for Bharat Biotech vaccine. This oxford thing is a dud.

选择巴拉特生物技术公司的疫苗吧。牛津疫苗没用。

Gaurav Rai

I think going with AstraZeneca is not such a great idea.

我认为选择阿斯利康疫苗并不是一个好主意。

Balananda Sivam

UK itself is not using this vaccine.

英国都没有使用这种疫苗。

Balananda Sivam

We are subjects for testing this vaccine?

拿我们来做试验吗？

Ayub Ali Khan

By the time India approveds any vaccine of Corona , it will go by it self

等到印度批准使用新冠疫苗时，病毒已经自行消失了

Asish Ray

With only 62% efficacy , this is not preferred...Better wait for Covaxn/Covishield which is supposed to have 90% efficacy...

These are likely to come within a month or so.

阿斯利康疫苗的有效性只有62%，不是首选……最好等Covaxn/Covishield疫苗，有效性应该能达到90%…可能还要一个月左右

Ravi Nair

Why has this vaccine not been approved anywhere in the world? Because it's efficacy and safety data is dubious! Serum Institute Lobby is pushing to get this vaccine approved in India since they have a huge number of doses lying useless in there warehouse! God save us from this wrath!

为什么其他国家都没有批准使用这种疫苗?

因为其疗效和安全性数据可疑!

血清研究所的游说团体正在极力促成这种疫苗在印度获得批准，他们有大量疫苗堆在仓库里!